Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[123I]beta-CIT
- Development stage
- Phase 2
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
A radioiodinated cocaine analog used as a radiotracer in SPECT imaging to visualize dopamine transporters (DAT) and serotonin transporters (SERT) in the brain. It has a physical half-life of approximately 13 hours and requires imaging around 20-30 hours after injection to achieve stable levels of striatal radioactivity. It's primarily used in research and clinical settings for evaluating patients with movement disorders like Parkinson's disease.
- Brand names
- DOPASCAN
- Other names
- 2beta-carbomethoxy-3beta-[4-iodophenyl]tropane
02
Targets
DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on [123I]beta-CIT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [123I]beta-CIT.